We work on some of the most complex molecules in development. Our scientists write about it, present on it, and share what they have learned, so you can move your program forward with more confidence. Drug product, nanomedicine, bioanalysis, drug substance. Written by the people who deliver these programs every day.
Live conferences and on-demand webinars where you can connect with our scientific team.
Join CHDR and Ardena on Oct 19, 2026 to see how biomarker validation and translational medicine demonstrate CNS target engagement in neurodegenerative disease.
Talk formulation, drug product and bioanalysis with our specialists at booth 2012.
Moving molecules from discovery into development, in San Diego.
Insights and perspectives from our team on industry trends and scientific advances.
Decisions across a drug program, from selecting a lead candidate to setting a clinical dose, rely on measuring the drug and its effects in biological samples. As a molecule moves through development, the method behind those measurements has to change with it. A research method that supports lead optimization is not the fully developed method […]
Delivery technology no longer just supports new therapies; it is one of the main things that make them possible. That was the shared conclusion of the final panel at Ardena’s Nanomedicine and Bioconjugation Symposium, held on September 15 and 16, 2026, in Oss, the Netherlands. Over two days, clinical researchers, academics, bioprocess engineers and bioanalytical […]
Nanomedicine has progressed far beyond its early role as an experimental drug-carrier toolbox. That is the premise of “Nanomedicine beyond carriers: devices, cells & living therapeutics”, a collaborative review published in Biomedical Microdevices on 8 September 2026, in the Special Issue dedicated to the NanoDDS 2025 conference. Silvie Meeuwissen, Director Process R&D and Manufacturing, Nanomedicines […]
Real-world examples of how our expertise has helped partners advance their programs.
When API content drops under accelerated stability conditions and known degradation products don’t account for the loss, development teams need answers quickly. This Ardena application note shows how SOLFORD®, a solid-state degradation technology developed and patented by RD&C, was applied to forced degradation and drug-excipient compatibility screening. The approach confirmed a stability-indicating method and identified […]
Proof of Structure (PoS) is the comprehensive analytical confirmation that a synthesized compound corresponds exactly to its intended chemical identity, including its molecular formula, connectivity, stereochemistry and purity profile. In the pharmaceutical industry, accurate characterization of a molecular structure, including its solid-state identity, is a fundamental requirement that underpins every stage of drug development, from […]
Poor aqueous solubility remains a formidable barrier in drug development, with approximately 90% of new chemical entities facing significant challenges in achieving effective bioavailability. To overcome these limitations, pharmaceutical developers frequently employ solubility enhancement techniques, ranging from particle size reduction to solid-state modifications and advanced formulation-based strategies. At Ardena, our approach emphasizes salt screening, lipid-based […]
In-depth scientific papers from our experts on emerging methods and technologies.
Delumping is an established operation in pharmaceutical manufacturing, used to produce more homogeneous, free-flowing powders across drug substance and drug product processes. When agglomeration is left unaddressed, it can affect powder flow, charging, homogeneity, downstream processing, cycle time and yield. In this technical paper, Kim Geurts, Scientist PR&D and Manufacturing, Enabling Chemistry, explains how Ardena […]
Nanomedicines demand tight control over particle properties, reproducibility, and scalability, yet conventional batch methods often struggle to deliver all three. In this whitepaper, Ardena’s nanomedicines experts Mark van Eldijk and Andy Bänziger explore how flow manufacturing can enable more consistent nanoparticle production, simplify scale-up, and support robust development pathways from early-stage research through GMP manufacturing. […]
The ICH has released a draft consolidated guideline (ICH Q1) that unifies the previous Q1A–Q1F series into a single global standard. This revision simplifies stability requirements, integrates lifecycle management, and expands the scope to advanced therapies and drug-device combinations. This whitepaper provides a clear overview of the key changes — from predictive tools and modeling […]
Conversations with our scientists and partners on drug development science.
What does it take to move innovative science from the lab toward the patient? In this episode of We Know Development™, Mark van Eldijk, Vice President of Science and Technology at Ardena, discusses nanoparticles, advanced drug development, and the challenges of translating complex technologies into medicines that can make a real impact. Discover the science, […]
Welcome to We Know Development™, a podcast from Ardena about the people, decisions, and expertise behind drug development. Drug development is often described through science, technology, quality, and regulation. All of those are essential. But behind every successful program are people making decisions, navigating uncertainty, solving complex challenges, and building trust. In We Know Development, […]
